Michigan Governor Signs Three Bills Addressing PBM and Insurer Discrimination Against 340B Entities and Contract Pharmacies

Michigan Gov. Gretchen Whitmer (D) signed three bills today that prohibit PBMs and insurance carriers from discriminating against 340B covered entities and contract pharmacies.

Michigan Gov. Gretchen Whitmer (D) signed three bills today that prohibit pharmacy benefit managers (PBMs) and insurance carriers from discriminating against 340B covered entities and their contract pharmacies.

HB 4348 says PBMs and insurers shall not prohibit entities or

Read More »

Federal Judge Denies Fla. Healthcare Providers’ Bid to Throw Out Gilead’s Suit Alleging 340B Fraud

A federal judge has denied a group of defendants’ motion to dismiss Gilead’s lawsuit against them alleging fraudulent 340B-related transactions of the company’s PrEP drugs.

A federal district judge in Florida has denied a group of defendants’ motion to dismiss Gilead’s lawsuit against them alleging fraudulent 340B-related transactions on the company’s HIV pre-exposure prophylaxis drugs Truvada and Descovy.

U.S. District Judge Aileen Cannon of the

Read More »

Pharma Consultant Sounds Alarm About Potential Sub-Zero 340B Prices on Some Brand Drugs Starting in 2024

A graph from BioCentury's issue brief shows Humira's 340B ceiling price falling to a penny after 2016.

In less than two years, brand drug companies that now must sell their products to 340B covered entities for a penny due to a history of price increases above inflation may have to start paying entities for their drugs instead

Read More »

AstraZeneca Court Ruling Means All Six of HRSA’s 340B Original Contract Pharmacy Violation Letters are Dead

After yesterday's court decision in AstraZeneca’s 340B contract pharmacy lawsuit, all six of HRSA's letters telling Astra, Lilly, Novartis, Novo Nordisk, Sanofi, and United Therapeutics that their actions are illegal are dead.

UPDATED Thursday, Feb. 17, 2022, 4:00 p.m. EDT—The U.S. Health Resources and Services Administration (HRSA) said this afternoon, “The 340B program is an essential component of the safety net system that helps make health care and prescription drugs more affordable

Read More »

Drug Makers Ask Judge Again to Dismiss 340B-Related Antitrust Charges

Insulin and diabetes drug manufacturers urged a federal judge again to dismiss 340B-related antitrust charges against them.

Insulin and diabetes drug manufacturers charged with federal and state price-fixing violations over their 340B contract pharmacy restrictions have again told a federal judge why they think she should dismiss the case.

AstraZeneca, Lilly, Novo Nordisk, and Sanofi filed their

Read More »

Merck Offering Refunds for 340B Overcharges

Merck is providing refunds to 340B covered entities for purchases of 17 products during the third quarter of 2020.

Drug manufacturer Merck is providing 340B covered entities with refunds for overcharges on 17 NDCs for purchases between Jan. 1 and March 31, 2019, the company says in a new public notice on the U.S. Health Resources and Services

Read More »

California Asks Judge to Dismiss 340B Health Centers’ Suit Challenging Medicaid Drug Payment Change

California says its consolidation of Medicaid prescription drug services under Medicaid fee for service (Medi-Cal Rx) does not deprive 340B health centers of revenue to which they are entitled.

California’s consolidation on Jan. 1 of all its Medicaid (Medi-Cal) prescription drug services under Medi-Cal fee for service does not violate federal law and does not deprive the state’s 340B health centers “of any reimbursement or revenue to which they

Read More »

Breaking News

Federal Judge Vacates HRSA’s Finding that AstraZeneca’s 340B Contract Pharmacy Policy Is Illegal

A federal district judge today struck down and vacated HRSA's May 2021 finding that AstraZeneca's 340B contract pharmacy policy violates the 340B statute.

A federal district judge in Wilmington, Del., today struck down and vacated the federal government’s finding that drug maker AstraZeneca’s conditions on 340B pricing when covered entities use contract pharmacies violates the 340B statute.

U.S. District Judge Leonard Stark of

Read More »

HHS Secretary Becerra Pledges to Keep Fighting Against 340B Contract Pharmacy Restrictions “Because it’s the Law”

HHS Secretary Xavier Becerra told health centers yesterday that “we’re going to continue to fight” drug manufacturers that restrict 340B pricing when covered entities use contract pharmacies “because it’s the law.”

U.S. Health and Human Services (HHS) Secretary Xavier Becerra said yesterday that “we’re going to continue to fight” drug manufacturers that restrict 340B pricing when covered entities use contract pharmacies “because it’s the law.”

Becerra’s Feb. 14 remarks about manufacturers’

Read More »

In a Win for Health Centers, 340B ADR Panel Says Proceedings Against AstraZeneca & Sanofi Must Go On

A 340B administrative dispute resolution (ADR) panel said it will not stop proceedings in the National Association of Community Health Centers’ complaint against AstraZeneca and Sanofi.

A 340B administrative dispute resolution (ADR) panel decided late last week that it will not stop proceedings in the National Association of Community Health Centers’ (NACHC) dispute-resolution petition over drug manufacturers AstraZeneca and Sanofi’s conditions on 340B pricing when covered

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report